AGL INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of agilon health
newsfilecorp.com
Want to monitor NGNE?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor NGNEneoleukin therapeutics, inc. , a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.